GSK (HAM:GS70) NonCurrent Deferred Liabilities: €0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:GS70 GSK PLC HAM:GS70
82 GF Score
Price €45.00
GF Value €38.91
! 1 Warning Sign
View Full Analysis

What is GSK NonCurrent Deferred Liabilities?

GSK HAM:GS70 +0.45% 82 NonCurrent Deferred Liabilities is €0 Mil as of Mar. 2026. GuruFocus rates HAM:GS70 with a GF Score™ of 82/100 and a GF Value™ of €38.91. The stock has 1 warning sign investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

GSK's non-current deferred liabilities for the quarter that ended in Mar. 2026 was €0 Mil.

GSK NonCurrent Deferred Liabilities Related Terms

GSK NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for GSK's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK NonCurrent Deferred Liabilities Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GSK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HAM:GS70
82GF Score
GSK PLC HAM:GS70
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of €0 Mil mean?
GSK (HAM:GS70) has a NonCurrent Deferred Liabilities of €0 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on GSK and its competitors.
Is GSK's NonCurrent Deferred Liabilities too high?
GSK's current NonCurrent Deferred Liabilities is €0 Mil. Overall, GSK has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does GSK's NonCurrent Deferred Liabilities compare to LLY and JNJ?
GSK's NonCurrent Deferred Liabilities of €0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Drug Manufacturers company?
A good NonCurrent Deferred Liabilities depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on GSK and its competitors. GSK's current NonCurrent Deferred Liabilities is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
GSK (HAM:GS70) has a current NonCurrent Deferred Liabilities of €0 Mil. The stock's GF Value™ is €38.91, compared to a current price of €45.00 — trading 15.7% above its estimated fair value. The current NonCurrent Deferred Liabilities is €0 Mil. GSK's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For GSK (HAM:GS70), the current NonCurrent Deferred Liabilities is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (HAM:GS70) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of €45.00 is trading 15.7% above its estimated GF Value™ of €38.91.

Key valuation signals for HAM:GS70:

  • NonCurrent Deferred Liabilities: €0 Mil
  • GF Value™: €38.91 vs. price of €45.00 (15.7% above fair value)
  • GF Score™: 82/100 with 1 warning sign

No single metric tells the full story. See the HAM:GS70 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
82GF Score

Get the complete analysis for HAM:GS70

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€45.00
Price
€38.91
GF Value